VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901
July 29, 2019 08:00 ET | VBI Vaccines, Inc.
— Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients— Initial immunologic data from Part B expected around year-end 2019— Expanded...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019
June 04, 2019 08:00 ET | VBI Vaccines, Inc.
  Well tolerated at all doses with no safety signalsThree patients in high dose (10 µg) cohort showed evidence of stable disease by MRI10 µg dose selected for Part B of the study, which is expected...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs
April 17, 2019 08:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Appoints Joanne Cordeiro to Board of Directors
April 11, 2019 16:05 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., April 11, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Late-Breaking Poster Presentation at EASL 2019
April 09, 2019 08:00 ET | VBI Vaccines, Inc.
Poster presentation to highlight data from three previously-conducted clinical studies of Sci-B-Vac®, VBI’s prophylactic Hepatitis B vaccineIn all three studies, seroprotection rates of more than 98%...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results
February 25, 2019 08:00 ET | VBI Vaccines, Inc.
Top-line data from Hepatitis B (Sci-B-Vac®) Phase 3 PROTECT trial expected mid-year 2019Encouraging early immunogenicity data from GBM Phase 1/2a supports advancing into Part B of the studyLicense and...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Third Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent GBM Patients
February 07, 2019 08:00 ET | VBI Vaccines, Inc.
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the study without modificationEnrollment is complete in the high-dose study arm of Part AExpanded immunologic...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Appoints Blaine McKee to Board of Directors
January 16, 2019 08:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate
December 20, 2018 08:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriter’s Option to Purchase Additional Shares for Aggregate Gross Proceeds of $42.9 Million
December 18, 2018 08:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...